Friday, May 31

Session Title: Pediatric Oncology I  
Session Type: Oral Abstract Session  
Date: Fri, June 31  
Location: S504  
Time: 2:45 PM – 5:45 PM  
Speaker Name: Seth E Karol, MD

- 3:57 PM – 4:09 PM  
  **Abstract 10004** Safety and activity of venetoclax in combination with high-dose cytarabine in children with relapsed or refractory acute myeloid leukemia.

Saturday, June 1

Session Title: Developmental Therapeutics and Tumor Biology (Nonimmuno)  
Session Type: Poster Session  
Date: Sat, June 1  
Location: Hall A  
Time: 8:00 AM – 11:00 AM  
Speaker Name: Salvatore Siena, MD

- **Abstract 3017** Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: Integrated analysis from three clinical trials. **Poster Board #9**

Session Title: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers  
Session Type: Oral Abstract Session  
Date: Sat, June 1  
Location: Hall D2  
Time: 1:15 PM – 4:15 PM  
Speaker Name: David J. Kwiatkowski, MD, PhD

- 2:15 PM – 2:27 PM  
  **Abstract 8503** Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).
**Session Title:** Targeting Breast Cancer: Breaking the Code  
**Session Type:** Clinical Science Symposium  
**Date:** Sat, June 1  
**Location:** Hall D1  
**Time:** 3:00 PM - 4:30 PM  
**Speaker Name:** Ian E. Krop, MD, PhD

- **3:48 PM - 4:00 PM**  
  **Abstract 1012** Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial.

---

**Sunday, June 2**

**Session Title:** Breast Cancer—Local/Regional/Adjuvant  
**Session Type:** Poster Session  
**Date:** Sun, June 2  
**Location:** Hall A  
**Time:** 8:00 AM - 11:00 AM  
**Speaker Name:** Andreas Schneeweiss, MD

- **Abstract 513** Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer. **Poster Board #5**

---

**Session Title:** Breast Cancer—Metastatic  
**Session Type:** Poster Session  
**Date:** Sun, June 2  
**Location:** Hall A  
**Time:** 8:00 AM - 11:00 AM  
**Speaker Name:** Sandra M. Swain, MD, FASCO; Binghe Xu, MD; Sylvia Adams, MD; Andreas Schneeweiss, MD

- **Abstract 1020** End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). **Poster Board #101**
- **Abstract 1026** A phase III, randomized, double-blind, placebo (Pla)-controlled study of pertuzumab (P) + trastuzumab (H) + docetaxel (D) versus Pla + H+ D in previously untreated HER2-positive locally recurrent/metastatic breast cancer (LR/MBC) (PUFFIN). **Poster Board #107**
- **Abstract 1067** Patient-reported outcomes (PROs) from the phase III IMpassion130 trial of atezolizumab (atezo) plus nabpaclitaxel (nP) in metastatic triple-negative breast cancer (mTNBC). **Poster Board #148**
- **Abstract 1068** IMpassion130: Expanded safety analysis from a P3 study of atezolizumab (A) + nabpaclitaxel (nP) in patients (pts) with treatment (tx)-naïve, locally advanced or metastatic triple-negative breast cancer (mTNBC). **Poster Board #149**
Session Title: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Session Type: Poster Session
Date: Sun, June 2
Location: Hall A
Time: 8:00 AM - 11:00 AM
Speaker Name: Benjamin J. Solomon, MBBS, PhD

- **Abstract TPS8569** ALINA: A phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IB–IIIA anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC). *Poster Board #325a*

Session Title: Lung Cancer—Non-Small Cell Metastatic
Session Type: Poster Session
Date: Sun, June 2
Location: Hall A
Time: 8:00 AM - 11:00 AM
Speaker Name: Mark A. Socinski, MD; Robert Charles Doebele, MD, PhD

- **Abstract 9012** IMpower150: Analysis of efficacy in patients (pts) with liver metastases (mets). *Poster Board #335*
- **Abstract 9070** Time-to-treatment discontinuation (TTD) and real-world progression-free survival (rwPFS) as endpoints for comparative efficacy analysis between entrectinib trial and crizotinib real-world ROS1 fusion-positive (ROS1+) NSCLC patients. *Poster Board #393*

Session Title: Pediatric Oncology II
Session Type: Oral Abstract Session
Date: Sun, June 2
Location: S504
Time: 8:00 AM - 11:00 AM
Speaker Name: Giles W. Robinson, MD

- **8:00 AM - 8:12 AM**
  - **Abstract 10009** Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.

Session Title: Plenary Session Including the Distinguished Achievement Award and Science of Oncology Award Lecture
Session Type: Plenary Session
Date: Sun, June 2
Location: Hall B1
Time: 1:00 PM - 4:00 PM
Chair and/or Co-Chairs: Suzanne George, MD; Monica M. Bertagnolli, MD, FACS, FASCO; Bruce E. Johnson, MD, FASCO; Robert J. Mayer, MD, FASCO; Joan S. Brugge, PhD; Blythe J.S. Adamson, PhD, MPH; Yousuf Zafar, MD, MHS, FASCO; Christopher Sweeney, MBBS; Tanya B. Dorff, MD; William D. Tap, MD; Jaap Verweij, MD, PhD, FASCO; Hedy L. Kindler, MD, FASCO; Wells A. Messersmith, FACP, MD
Monday, June 3

Session Title: Breast Cancer—Local/Regional/Adjuvant  
Session Type: Oral Abstract Session  
Date: Mon, June 3  
Location: Hall D2  
Time: 9:45 AM - 12:45 PM  
Speaker Name: Sara A. Hurvitz, MD

- 9:45 AM - 9:57 AM  
  Abstract 500 Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome results from the phase III KRISTINE study.

Session Title: Genitourinary (Nonprostate) Cancer  
Session Type: Poster Session  
Date: Mon, June 3  
Location: Hall A  
Time: 1:15 PM - 4:15 PM  
Speaker Name: Cora N. Sternberg, MD, FACP

- Abstract 4519 Clinical outcomes according to PD-L1 status and age in the prospective international SAUL study of atezolizumab (atezo) for locally advanced or metastatic urothelial carcinoma (UC) or non-UC of the urinary tract. Poster Board #345

Tuesday, June 4

Session Title: Breast Cancer—Metastatic  
Session Type: Oral Abstract Session  
Date: Tue, June 4  
Location: Hall D1  
Time: 9:45 AM - 12:45 PM  
Speaker Name: Peter Schmid, MD, PhD, FCRP

- 10:45 AM - 10:57 AM  
  Abstract 1003 IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).
**Session Title:** Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia  
**Session Type:** Oral Abstract Session  
**Date:** Tue, June 4  
**Location:** E451  
**Time:** 9:45 AM - 12:45 PM  
**Speaker Name:** Kirsten Fischer, MD; Catherine Diefenbach

- **10:09 AM - 10:21 AM**  
  **Abstract 7502** Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRD−) in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) and comorbidities.

- **11:33 AM - 11:45 AM**  
  **Abstract 7505** Polatuzumab vedotin (Pola) + obinutuzumab (G) and lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL): Interim analysis of a phase Ib/II trial.